serclutamab talirine

Serclutamab talirine is an antibody-drug conjugate (ADC) developed by AbbVie for the treatment of advanced solid tumors, including glioblastoma, colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, bladder carcinoma, cervical cancer, esophageal cancer, kidney cancer, and sarcoma. The drug consists of an affinity-matured anti-EGFR antibody (AM-1-ABT-806) linked to a highly potent DNA cross-linking agent from the pyrrolobenzodiazepine dimer class (talirine), using a cathepsin-B cleavable linker. Upon binding to activated epidermal growth factor receptor (EGFR) on tumor cells and internalization, talirine is released intracellularly where it induces DNA inter-strand cross-links leading to cytotoxicity. Notably, the released toxin is cell-permeant and can diffuse into adjacent non-EGFR-expressing cells ("bystander effect"), enhancing its antitumor activity in heterogeneous tumors such as glioblastoma[1][3][4][5][7]. Serclutamab talirine has been evaluated in phase I clinical trials for advanced glioblastoma and other EGFR-overexpressing solid tumors[2][3].

Other names

AM-1-ABT-806 (antibody component)